The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

A UK company developing technology spun out of the University of Queensland is poised for growth after being acquired by ...

Sanofi and GlaxoSmithKline are working together to create a COVID-19 vaccine with funding from HHS, the drugmakers said April 14. The drugmakers said they will combine technology Sanofi has used ...

Sanofi and GlaxoSmithKline said Oct. 28 that they will provide 200 million doses of their COVID-19 vaccine to the World Health Organization's Covax initiative if the vaccine receives regulatory ...

Image Source: Zacks Investment Research. Sanofi Deal Breathes New Life Into NVAX Stock. Beginning next year, Sanofi will gain rights to co-market Novavax’s COVID-19 vaccine globally, except in ...

Drugmakers are racing to develop what would be a lucrative prize, but have sought financial support to mitigate the risks. Sanofi is working on two vaccine projects against COVID-19.

LONDON (AP) — Drugmakers Sanofi and GlaxoSmithKline said Friday that their potential COVID-19 vaccine won’t be ready until late next year because they need to improve the shot’s ...